Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 3, 2023.

The chief training and education officer at the Parkinson’s Foundation discussed the importance of educating healthcare professionals on different specialists that play a role in Parkinson disease management. [WATCH TIME: 2 minutes]

In celebration of Women’s Physician Day, held February 3, 2022, take a look back at some of the latest conversations and news that were driven and delivered by women in neurology.

The director of the Montefiore Einstein Center for the Aging Brain provided insight on expanding the use of the 5-Cog tool, and whether it can be used for other conditions like HIV or COVID-19. [WATCH TIME: 3 minutes]

Treatment with deep brain stimulation resulted in improvements in mean motor scores, reductions levodopa equivalent dosage, and a decrease in neuropsychiatric features.

Majority of women’s healthcare providers reported in a survey feeling either somewhat or very comfortable with recommending or continuing acute treatments for pregnant patients with migraine.

The expert panel comments on ideal patient profiles for SMA treatment with nusinersen, onasemnogene abeparvovec, and risdiplam. O painel de especialistas comenta os perfis ideais de pacientes para tratamento da atrofia muscular espinhal com nusinersena, onasemnogeno abeparvoveque e risdiplam.

Drs Rodrigo de Holanda Mendonça and Adriana Banzzatto Ortega discuss clinical trial data with nusinersen, onasemnogene abeparvovec, and risdiplam. Drs Rodrigo de Holanda Mendonça e Adriana Banzzatto Ortega discutem dados de testes clínicos com nusinersena, onasemnogeno abeparvoveque e risdiplam.

Recruitment has begun for REGENXBIO's AFFINITY BEYOND clinical trial assessing the prevalence of AAV8 antibodies in male patients with Duchenne muscular dystrophy.

Dr Atri comments on observation of amyloid related imaging abnormalities (ARIA) seen with many Alzheimer’s disease treatments and shares his thoughts on management of ARIA.

Dr Atri discusses aducanumab, first FDA approved anti-amyloid-beta antibody for treatment of Alzheimer’s disease.

The pediatric neurologist at Nationwide Children's Hospital talked about current gaps and potential treatment approvals in epilepsy care for 2023. [WATCH TIME: 4 minutes]

An exergaming program that spanned 8 weeks showed positive effects for patients with multiple sclerosis both with and without restless legs syndrome.

The chief training and education officer at the Parkinson’s Foundation provided perspective on the vast types of medical professionals who can learn from the organization’s new education series. [WATCH TIME: 4 minutes]

With a PDUFA date of October 26, 2023, the FDA will review data from the phase 2b VISION-DMD study, in which vamorolone met its primary end point in change in TTSTAND velocity.

Branaplam, an mRNA splicing modifier, joins the many unsuccessful agents for Huntington disease as biopharma continues to be challenged with trial holds and failures.

Take a look at 5 of the most-anticipated clinical trial data readouts expected in 2023 that neurology health care professionals should keep their eyes on.

Donald Whiting, MD, chair of Allegheny Health Network’s Neurosciences Institute, provided insight on ADvance II, a multinational trial exploring the use of deep brain stimulation in patients with mild Alzheimer disease.

The psychologist and professor in the department of rehabilitation medicine at the University of Washington shared her perspective on the state of mental health care in multiple sclerosis. [WATCH TIME: 4 minutes]

The executive direct of Cure CMD discussed the state of care for patients with congenital muscular dystrophies, the need for new treatments, and the patience with gene therapies.

A cross-sectional and longitudinal comparative analysis suggests a subclinical neurodegenerative process may occur in MOG antibody disease based on a distinct pattern of brain atrophy.

Data from a cohort of more than 8000 participants suggest that older adults with less optimal sleep duration might benefit from moderate napping for their cognitive functions.

The pediatric neurologist at Nationwide Children's Hospital talked about the year-over-year changes in day-to-day clinical practice of patients with epilepsy. [WATCH TIME: 4 minutes]

In addition to showing a tolerable safety profile, EQU-001 resulted in reduced IL-17 and IL-1b plasma levels relative to baseline and limited the ability of peripheral mononuclear cells to secrete additional pro-inflammatory cytokines.

The chief training and education officer at the Parkinson’s Foundation provided perspective on a recently launched online program aimed at educating healthcare professionals. [WATCH TIME: 3 minutes]